Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-IFN Alpha in HBeAg Negative CHB After Stopping NA Therapy
NCT03123653Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Mar 2017
- Primary completion
- Sep 2019
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label, single-arm trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Sustained Virological Response. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03123653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123653.